Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients

Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinoma patients to determine the main pathway of metabolism of belinostat. The pharmacokinetics of belinostat in liver cancer patients were characterized by rapid plasma clearance of belinostat with extensive metabolism with more than 4-fold greater relative systemic exposure of major metabolite, belinostat glucuronide than that of belinostat. There was significant interindividual variability of belinostat glucuronidation. The major pathway of metabolism involves UGT1A1-mediated glucuronidation and a good correlation has been identified between belinostat glucuronide formation and glucuronidation of known UGT1A1 substrates. In addition, liver microsomes harboring UGT1A1*28 alleles have lower glucuronidation activity for belinostat compared to those with wildtype UGT1A1. The main metabolic pathway of belinostat is through glucuronidation mediated primarily by UGT1A1, a highly polymorphic enzyme. The clinical significance of this finding remains to be determined. Trial Registration ClinicalTrials.gov NCT00321594

[1]  B. Goh,et al.  Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Ling-Zhi Wang,et al.  Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer , 2011, Pharmacogenetics and genomics.

[3]  Tae Won Kim,et al.  The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models , 2011, Cancer Chemotherapy and Pharmacology.

[4]  S. Steinberg,et al.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.

[5]  N. Tanji,et al.  Potential of histone deacetylase inhibitors for bladder cancer treatment , 2011, Expert review of anticancer therapy.

[6]  G. Giaccone,et al.  Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Dent,et al.  Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim , 2011, British journal of haematology.

[8]  H. Prince,et al.  New drug therapies in peripheral T-cell lymphoma , 2011, Expert review of anticancer therapy.

[9]  Wei Zhang,et al.  A pharmacogenetic study of vorinostat glucuronidation. , 2010, Pharmacogenetics and genomics.

[10]  B. Goh,et al.  A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  H. Mackay,et al.  Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. , 2010, European journal of cancer.

[12]  S. Bapat.  Modulation of gene expression in ovarian cancer by active and repressive histone marks. , 2010, Epigenomics.

[13]  Yasuhiro Aoki,et al.  Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers , 2009, Drug Metabolism and Disposition.

[14]  S. Bates,et al.  Epigenetic Modifiers: Basic Understanding and Clinical Development , 2009, Clinical Cancer Research.

[15]  S. Clive,et al.  Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [14C]-panobinostat. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Dellinger,et al.  Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. , 2009, Cancer research.

[17]  D. Gandara,et al.  Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Robert Brown,et al.  A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[19]  Richard Pazdur,et al.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. , 2007, The oncologist.

[20]  Joseph G Ibrahim,et al.  UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.

[21]  M. Ratain,et al.  UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers , 2007, Pharmacogenetics and genomics.

[22]  M. Sehested,et al.  The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo , 2007, Cancer Chemotherapy and Pharmacology.

[23]  D. Musson,et al.  High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. , 2005, Rapid communications in mass spectrometry : RCM.

[24]  C. Monneret.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[25]  M. Ratain,et al.  Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes , 2005, Pharmacogenetics and genomics.

[26]  Gordon K Smyth,et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Furge,et al.  Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. , 2004, International journal of oncology.

[29]  Marie Joseph,et al.  Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Ciotti,et al.  Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides. , 1999, Carcinogenesis.

[31]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[32]  E. Beutler,et al.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Manns,et al.  Expression of the UDP-glucuronosyltransferase 1A Locus in Human Colon , 1998, The Journal of Biological Chemistry.

[34]  S. R. Babu,et al.  Glucuronidation of N-hydroxy metabolites of N-acetylbenzidine. , 1995, Carcinogenesis.

[35]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[36]  J. Dipersio,et al.  Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS) , 2011, Annals of Hematology.

[37]  T. Shiraga,et al.  Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. , 2005, Biological & pharmaceutical bulletin.